Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes

Exclusion Criteria

• •NPH (neutral protamine hagedorn) insulin
• •Use of any medication that at the discretion of the investigator is deemed to interfere with the trial.
• •Current treatment of a primary seizure disorder
• •Coronary artery disease or heart failure, unless written clearance is received from a cardiologist.
• •Hemophilia or any other bleeding disorder
• •A known medical condition, which in the opinion of the investigator or designee, would put the participant or study at risk such as the following examples:
• •* Inpatient psychiatric treatment in the past 6 months
• •* Presence of a known adrenal disorder
• •* Abnormal liver function test results (Transaminase \>3 times the upper limit of normal)
• •* Abnormal renal function test results (calculated GFR \<60 mL/min/1.73m2).
• •* Active gastroparesis requiring medical therapy
• •* Uncontrolled thyroid disease (TSH undetectable or \>10 mlU/L).
• •* Abuse of alcohol or recreational drugs
• •* Infectious process not anticipated to be resolved prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis, deep tissue infection).
• •* Uncontrolled arterial hypertension (Resting diastolic blood pressure \>100 mmHg and/or systolic blood pressure \>180 mmHg).
• •* Uncontrolled microvascular complications such as current active proliferative diabetic retinopathy defined as proliferative retinopathy requiring treatment (e.g. laser therapy or VEGF inhibitor injections) in the past 12 months.
• •A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol.
• •Not familiar with smart phone technology
• •Current use of the following drugs and supplements:
• •* Oral steroids
• •* Any other medication that the investigator believes is a contraindication to the subject's participation
• •Participation in another pharmaceutical or device trial at the time of enrollment or during the study.